Diagnosis and medical management of ocular surface squamous neoplasia

ABSTRACT Introduction: Topical chemotherapy has gained popularity among clinicians for the treatment of ocular surface squamous neoplasia (OSSN) . The principal topical chemotherapy agents used in the management of OSSN are interferon-α2b, 5-fluorouracil, and mitomycin C. High-resolution optical coherence tomography (HR-OCT) is a non-invasive technique that can differentiate OSSN from other ocular surface lesions. Areas covered: This review highlights the current regimens and diagnostic modalities used in managing OSSN. A review of the literature was performed using the keywords ‘conjunctival intraepithelial neoplasia’, ‘ocular surface squamous neoplasia’, ‘optical coherence tomography’, ‘interferon-α2b’, ‘5-fluorouracil’ and ‘mitomycin C’. Expert commentary: Topical chemotherapy for OSSN can be used as primary therapy, for chemoreduction prior to surgical excision, and postoperatively to prevent tumor recurrence. It has the advantage of treating microscopic disease as well as large tumors. HR-OCT provides an ‘optical biopsy’ that can assist in diagnosis and guide management of OSSN lesions.

[1]  Madhura G. Joag,et al.  Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia. , 2016, Ophthalmology.

[2]  G. Nuovo,et al.  Human Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia. , 2015, Ophthalmology.

[3]  L. Asena,et al.  Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[4]  C. Karp,et al.  Treatment of Ocular Surface Squamous Neoplasia With Topical Aloe vera Drops , 2015, Cornea.

[5]  S. Deng,et al.  Topical Interferon Alpha-2b for Treatment of Noninvasive Ocular Surface Squamous Neoplasia with 360° Limbal Involvement , 2014, Journal of ophthalmic & vision research.

[6]  C. S. Moon,et al.  Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. , 2014, Ophthalmology.

[7]  J. Muecke,et al.  Long‐term outcomes after adjunctive topical 5‐flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia , 2014, Clinical & experimental ophthalmology.

[8]  H. Weiss,et al.  Diagnosing Ocular Surface Squamous Neoplasia in East Africa , 2014, Ophthalmology.

[9]  Stephen J. Vincent,et al.  Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b. , 2014, American journal of ophthalmology.

[10]  D. Stone,et al.  Ocular Surface Squamous Neoplasia: A Survey of Changes in the Standard of Care From 2003 to 2012 , 2013, Cornea.

[11]  H. Carrara,et al.  Identification of ocular surface squamous neoplasia by in vivo staining with methylene blue , 2013, British Journal of Ophthalmology.

[12]  I. Rennie,et al.  Ocular surface squamous neoplasia: analysis of 78 cases from a UK ocular oncology centre , 2013, British Journal of Ophthalmology.

[13]  S. Kase,et al.  Expression of αB-crystallin and vascular endothelial growth factor in conjunctival squamous cell carcinoma. , 2013, Anticancer research.

[14]  H. Pazarlı,et al.  Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[15]  S. Feizi,et al.  Subconjunctival Bevacizumab Injection for Ocular Surface Squamous Neoplasia , 2013, Cornea.

[16]  Sander R. Dubovy,et al.  Diagnosis of ocular surface lesions using ultra-high-resolution optical coherence tomography. , 2013, Ophthalmology.

[17]  Sander R. Dubovy,et al.  Prevalence, treatment, and outcomes of coexistent ocular surface squamous neoplasia and pterygium. , 2013, Ophthalmology.

[18]  Sanket U. Shah,et al.  Interferon for Ocular Surface Squamous Neoplasia in 81 Cases: Outcomes Based on the American Joint Committee on Cancer Classification , 2013, Cornea.

[19]  D. Stone,et al.  Intralesional bevacizumab use for invasive ocular surface squamous neoplasia. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[20]  M. Coroneo,et al.  Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up. , 2012, Ophthalmology.

[21]  Sander R. Dubovy,et al.  Clinicopathologic correlation of ocular surface squamous neoplasms at Bascom Palmer Eye Institute: 2001 to 2010. , 2012, Ophthalmology.

[22]  C. Abnet,et al.  Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP Diet and Health Study , 2012, Ecancermedicalscience.

[23]  Sander R. Dubovy,et al.  Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. , 2012, Ophthalmology.

[24]  P. Finger,et al.  Refractory Squamous Cell Carcinoma of the Conjunctiva Treated With Subconjunctival Ranibizumab (Lucentis): A Two-Year Study , 2012, Ophthalmic plastic and reconstructive surgery.

[25]  N. Girolamo Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia , 2012, Eye.

[26]  M. David,et al.  Immunomodulatory functions of type I interferons , 2012, Nature Reviews Immunology.

[27]  Sander R. Dubovy,et al.  Ultra-high resolution optical coherence tomography for differentiation of ocular surface squamous neoplasia and pterygia. , 2011, Ophthalmology.

[28]  E. Midena,et al.  In vivo confocal microscopy of ocular surface squamous neoplasia , 2011, Eye.

[29]  J. Muecke,et al.  Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia , 2011, British Journal of Ophthalmology.

[30]  K. Goins,et al.  Treatment of Ocular Surface Squamous Cell Intraepithelial Neoplasia With and Without Mitomycin C , 2011, Cornea.

[31]  A. Galor,et al.  Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review. , 2010, Ophthalmology.

[32]  E. Midena,et al.  Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study , 2010, British Journal of Ophthalmology.

[33]  A. Galor,et al.  Pegylated Interferon Alpha 2b for Treatment of Ocular Surface Squamous Neoplasia: A Pilot Study , 2010, Ocular immunology and inflammation.

[34]  A. Al-Barrag,et al.  5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea , 2010, Clinical ophthalmology.

[35]  D. Lockington,et al.  Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications , 2010, British Journal of Ophthalmology.

[36]  A. Gupta,et al.  Treatment of ocular surface squamous neoplasia with Mitomycin C , 2010, British Journal of Ophthalmology.

[37]  A. Labbé,et al.  [Contribution of in vivo confocal microscopy to diagnosis of invasive ocular surface squamous neoplasia: a case report]. , 2010, Journal francais d'ophtalmologie.

[38]  S. Mccormick,et al.  The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia. , 2009, American journal of ophthalmology.

[39]  J. N. Barros,et al.  Long-Term Results of Topical Mitomycin C 0.02% for Primary and Recurrent Conjunctival-Corneal Intraepithelial Neoplasia , 2009, Ophthalmic plastic and reconstructive surgery.

[40]  A. Galor,et al.  Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study , 2009, British Journal of Ophthalmology.

[41]  P. Finger,et al.  Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension , 2009, British Journal of Ophthalmology.

[42]  W. Feuer,et al.  Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. , 2008, Ophthalmology.

[43]  J. Chodosh,et al.  Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. , 2008, Ophthalmology.

[44]  V. Huerva,et al.  Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. , 2008, Journal francais d'ophtalmologie.

[45]  L. Hirst Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution. , 2007, Ophthalmology.

[46]  J. Muecke,et al.  Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia , 2006, British Journal of Ophthalmology.

[47]  J. Chodosh,et al.  Ocular Surface Squamous Neoplasia: A Standard of Care Survey , 2005, Cornea.

[48]  J. Pe’er Ocular surface squamous neoplasia. , 2005, Ophthalmology clinics of North America.

[49]  S. Seregard,et al.  Epiphora as a side effect of topical mitomycin C , 2004, British Journal of Ophthalmology.

[50]  Michael D. Boehm,et al.  Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. , 2004, Ophthalmology.

[51]  C. Shields,et al.  Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors. , 2004, Ophthalmology.

[52]  B. W. Dudney,et al.  Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. , 2004, American journal of ophthalmology.

[53]  J. Muecke,et al.  Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia , 2003, The British journal of ophthalmology.

[54]  M. Macsai,et al.  Ocular surface squamous neoplasia: a review. , 2003, Cornea.

[55]  N. Sonenberg,et al.  Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons* , 2003, Journal of Biological Chemistry.

[56]  C. Shields,et al.  Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. , 2002, American journal of ophthalmology.

[57]  J. Pe’er,et al.  Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma. , 2002, Ophthalmology.

[58]  G. Nuovo,et al.  Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. , 2002, Ophthalmology.

[59]  S. Tseng,et al.  Successful Management of Conjunctival Intraepithelial Neoplasia by Interferon α-2b , 2002 .

[60]  E. F. Smith,et al.  Regression of Presumed Primary Conjunctival and Corneal Intraepithelial Neoplasia With Topical Interferon Alpha-2b , 2002, Cornea.

[61]  S. Chatterjee,et al.  Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias , 2002, The British journal of ophthalmology.

[62]  C. Siganos,et al.  The Intraoperative Use of Mitomycin-C in Excision of Ocular Surface Neoplasia With or Without Limbal Autograft Transplantation , 2002, Cornea.

[63]  C. Karp,et al.  Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon α-2b , 2001 .

[64]  R. Yeatts,et al.  5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. , 2000, Ophthalmology.

[65]  P. Boccato,et al.  Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil. , 1997, Archives of ophthalmology.

[66]  J. Sugar,et al.  Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. , 1997, Ophthalmology.

[67]  J. Darnell STATs and gene regulation. , 1997, Science.

[68]  M. Wilson,et al.  Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. , 1997, American journal of ophthalmology.

[69]  C. Shields,et al.  Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. , 1997, Archives of ophthalmology.

[70]  G. Snibson,et al.  Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. , 1997, Ophthalmology.

[71]  J. Goedert,et al.  Epidemiology of squamous cell conjunctival cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[72]  S. Lewallen,et al.  Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi. , 1996, The British journal of ophthalmology.

[73]  V. Beral,et al.  Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye , 1996, The Lancet.

[74]  I. Scott,et al.  Conjunctival intraepithelial neoplasia : A possible marker for human immunodeficiency virus infection ? , 1996 .

[75]  S. L. Maskin Regression of limbal epithelial dysplasia with topical interferon. , 1994, Archives of ophthalmology.

[76]  A. Green,et al.  Risk factors in the development of ocular surface epithelial dysplasia. , 1994, Ophthalmology.

[77]  L. Hirst,et al.  Incidence of ocular surface epithelial dysplasia in metropolitan Brisbane. A 10-year survey. , 1992, Archives of ophthalmology.

[78]  R. Keizer,et al.  Topical application of 5-Fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid , 1986, Documenta Ophthalmologica.

[79]  J. Erie,et al.  Conjunctival and corneal intraepithelial and invasive neoplasia. , 1986, Ophthalmology.

[80]  D. Gaasterland,et al.  Ocular involvement in xeroderma pigmentosum. , 1982, Ophthalmology.

[81]  J. A. Burns,et al.  Punctal-canalicular stenosis related to systemic fluorouracil therapy. , 1981, Archives of ophthalmology.

[82]  K. Cantell,et al.  Synthesis in E. coli of a polypeptide with human leukocyte interferon activity , 1980, Nature.

[83]  J. Muecke,et al.  Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy , 2015, Clinical & experimental ophthalmology.

[84]  Benjamin J. Thomas,et al.  Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia. , 2014, The ocular surface.

[85]  R. Casson,et al.  The Clinical Applications of Fluorouracil in Ophthalmic Practice , 2012, Drugs.

[86]  A. Eggermont,et al.  Redefining the role of interferon in the treatment of malignant diseases. , 2010, European journal of cancer.

[87]  L. Zografos,et al.  Topical retinoic acid in dysplastic and metaplastic keratinization of corneoconjunctival epithelium , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[88]  M. Uiprasertkul,et al.  Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. , 2005, Cornea.

[89]  C. Shields,et al.  Chemoreduction with topical mitomycin C prior to resection of extensive squamous cell carcinoma of the conjunctiva. , 2005, Archives of ophthalmology.

[90]  S. Tseng,et al.  Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. , 2002, Japanese journal of ophthalmology.

[91]  C. Karp,et al.  Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. , 2001, Ophthalmology.

[92]  C. Karp,et al.  Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. , 1999, Ophthalmology.

[93]  F. Hu,et al.  Interferon treatment for corneolimbal squamous dysplasia. , 1998, American journal of ophthalmology.